Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

被引：2

作者：

Gomez-Labrador, Celia ^{[1
,2
]}

Ricart, Elena ^{[3
,4
]}

Iborra, Marisa ^{[5
]}

Iglesias, Eva ^{[6
]}

Martin-Arranz, Maria Dolores ^{[7
]}

de Castro, Luisa ^{[8
]}

De Francisco, Ruth ^{[9
,10
]}

Garcia-Alonso, Francisco Javier ^{[11
]}

Sanahuja, Ana ^{[12
]}

Gargallo-Puyuelo, Carla J. ^{[13
]}

Mesonero, Francisco ^{[14
]}

Casanova, Maria Jose ^{[1
,2
]}

Manosa, Miriam ^{[15
,16
]}

Rivero, Montserrat ^{[17
,18
]}

Calvo, Marta ^{[19
]}

Sierra-Ausin, Monica ^{[20
]}

Gonzalez-Munoza, Carlos ^{[21
]}

Calvet, Xavier ^{[22
,23
]}

Garcia-Lopez, Santiago ^{[24
,25
]}

Guardiola, Jordi ^{[26
]}

Garcia, Lara Arias ^{[27
]}

Marquez-Mosquera, Lucia ^{[28
,29
]}

Gutierrez, Ana ^{[30
]}

Zabana, Yamile ^{[31
,32
]}

Navarro-Llavat, Merce ^{[33
]}

Poyatos, Rufo Lorente ^{[34
]}

Piqueras, Marta ^{[35
]}

Torrealba, Leyanira ^{[36
]}

Bermejo, Fernando ^{[37
]}

Ponferrada-Diaz, Angel ^{[38
]}

Perez-Calle, Jose L. ^{[39
]}

Barreiro-de Acosta, Manuel ^{[40
]}

Tejido, Coral ^{[41
]}

Cabriada, Jose Luis ^{[42
]}

Marin-Jimenez, Ignacio ^{[43
]}

Roncero, Oscar ^{[44
]}

Ber, Yolanda ^{[45
]}

Fernandez-Salazar, Luis ^{[46
]}

Aler, Blau Camps ^{[47
]}

Lucendo, Alfredo J. ^{[48
,49
]}

Llao, Jordina ^{[50
]}

Bujanda, Luis ^{[51
,52
]}

Villafranca, Carmen Munoz ^{[53
]}

Domenech, Eugeni ^{[15
,16
,54
]}

Chaparro, Maria ^{[1
,2
]}

Gisbert, Javier P. ^{[1
,2
]}

机构：

[1] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS Princesa,Gastro, Gastroenterol Unit, Madrid 28006, Spain

[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28006, Spain

[3] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Gastroenterol Unit, Barcelona 08036, Spain

[4] CIBEREHD, Barcelona 08036, Spain

[5] Hosp Univ & Politecn La Fe, Gastroenterol Unit, Valencia 46026, Spain

[6] Hosp Univ Reina Sofia, Gastroenterol Unit, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba 14004, Spain

[7] Univ Autonoma Madrid, Hosp Univ La Paz, Hosp La Paz, Gastroenterol Unit,Inst Hlth Res, Madrid 28046, Spain

[8] UVIGO, Gastroenterol Unit, Hosp Alvaro Cunqueiro, Grp Invest Patol Digest,Inst Invest Sanitaria Gali, Vigo 36312, Spain

[9] Hosp Univ Cent Asturias, Gastroenterol Unit, Oviedo 33011, Spain

[10] Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain

[11] Hosp Univ Rio Hortega, Gastroenterol Unit, Valladolid 47012, Spain

[12] Hosp Clin Univ Valencia, Gastroenterol Unit, Valencia 46010, Spain

[13] Hosp Clin Univ Lozano Blesa, Gastroenterol Unit, IIS Aragon, Zaragoza 50009, Spain

[14] Hosp Univ Ramon y Cajal, Gastroenterol Unit, Madrid 28034, Spain

[15] Hosp Badalona Germans Trias & Pujol, Gastroenterol Unit, Badalona 08916, Spain

[16] CIBEREHD, Badalona 08916, Spain

[17] Hosp Univ Valdecilla, Gastroenterol Unit, Santander 39008, Spain

[18] Inst Invest Sanitaria Valdecilla IDIVAL, Santander 39008, Spain

[19] Hosp Univ Puerta de Hierro Majadahonda, Gastroenterol Unit, Madrid 28222, Spain

[20] Complejo Asistencial Univ Leon, Gastroenterol Unit, Leon 24008, Spain

[21] Hosp Santa Creu & Sant Pau, Gastroenterol Unit, Barcelona 08025, Spain

[22] Univ Autonoma Barcelona, Gastroenterol Unit, Hosp Univ, Inst Invest & Innovacio Parc Tauli,Dept Med,Parc T, Sabadell, Spain

[23] CIBEREHD, Sabadell 08208, Spain

[24] Hosp Univ Miguel Servet, Gastroenterol Unit, Zaragoza 50009, Spain

[25] Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza 50009, Spain

[26] Univ Barcelona, Hosp Univ Bellvitge, Gastroenterol Unit, Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08907, Spain

[27] Hosp Univ Burgos, Gastroenterol Unit, Burgos 09006, Spain

[28] Hosp Mar, Gastroenterol Unit, Barcelona, Spain

[29] IMIM Hosp Mar, Med Res Inst, Barcelona 08003, Spain

[30] Hosp Gen Univ Alicante, Gastroenterol Unit, CIBEREHD, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante 03010, Spain

[31] Hosp Univ Mutua Terrassa, Gastroenterol Unit, Terrassa 08221, Spain

[32] CIBEREHD, Terrassa 08221, Spain

[33] Complex Hosp Univ Moises Broggi, Gastroenterol Unit, Barcelona 08970, Spain

[34] Hosp Gen Univ Ciudad Real, Gastroenterol Unit, Ciudad Real 13005, Spain

[35] Consorci Sanitari Terrassa, Gastroenterol Unit, Terrassa 08227, Spain

[36] Hosp Univ Dr Josep Trueta, Gastroenterol Unit, Hosp Univ Dr, Girona 17007, Spain

[37] Hosp Univ Fuenlabrada, Gastroenterol Unit, Madrid 28942, Spain

[38] Hosp Univ Infanta Leonor, Gastroenterol Unit, Madrid 28031, Spain

[39] Hosp Univ Fdn Alcorcon, Gastroenterol Unit, Madrid 28922, Spain

[40] Hosp Clin Univ Santiago de Compostela, Gastroenterol Unit, Santiago De Compostela 15706, Spain

[41] Complexo Hosp Univ Ourense, Gastroenterol Unit, Orense 32005, Spain

[42] Hosp Galdakao Usansolo, Gastroenterol Unit, Galdakao 48960, Spain

[43] Univ Complutense Madrid, Hosp Gregorio Maranon, Gastroenterol Unit, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid 28007, Spain

[44] Complejo Hosp Mancha Ctr, Gastroenterol Unit, Alcazar De San Juan 13600, Spain

[45] Hosp Univ San Jorge, Gastroenterol Unit, Huesca 22004, Spain

[46] Univ Valladolid, Hosp Clin Univ Valladolid SACYL, Gastroenterol Unit, Valladolid 47003, Spain

[47] Hosp Gen Granollers, Gastroenterol Unit, Granollers 08402, Spain

[48] Hosp Gen Tomelloso, Gastroenterol Unit, Inst Invest Sanitaria Castilla La Mancha IDISCAM, Tomelloso 13700, Spain

[49] CIBEREHD, Tomelloso 13700, Spain

[50] Althaia Xarxa Assistencial Univ Manresa, Gastroenterol Unit, Barcelona 08243, Spain

来源：

PHARMACEUTICS | 2024年 / 16卷 / 05期

关键词：

biologics; biosimilars; targeted therapy; inflammatory bowel disease; Crohn's disease; ulcerative colitis; trends; positioning; MAINTENANCE THERAPY; CROHNS-DISEASE; ADALIMUMAB; INFLIXIMAB; INDUCTION; MODERATE; VEDOLIZUMAB;

D O I：

10.3390/pharmaceutics16050629

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.

引用

页数：17

共 35 条

[1] Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? [J].